Market capitalization | $10.43m |
Enterprise Value | $7.87m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.36 |
P/S ratio (TTM) P/S ratio | 0.48 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 32.21% |
Revenue (TTM) Revenue | $21.57m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
1 Analyst has issued a forecast Agile Therapeutics, Inc.:
1 Analyst has issued a forecast Agile Therapeutics, Inc.:
Jun '24 |
+/-
%
|
||
Revenue | 22 22 |
32%
32%
|
|
Gross Profit | 14 14 |
54%
54%
|
|
EBITDA | -13 -13 |
49%
49%
|
EBIT (Operating Income) EBIT | -14 -14 |
48%
48%
|
Net Profit | -16 -16 |
52%
52%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
Head office | United States |
CEO | Robert Spina |
Employees | 19 |
Founded | 1997 |
Website | www.agiletherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.